Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$556.03 USD

556.03
46,872

+6.76 (1.23%)

Updated Jul 29, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

    Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand

    Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.

      Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

      Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.

        Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

        Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

          Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates

          We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.

            ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth

            ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.

              PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates

              PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.

                PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up

                Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.

                  IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up

                  IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.

                    NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down

                    NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.

                      Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                      At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.

                        Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

                        Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.

                          QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2

                          QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.

                            Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance

                            Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.

                              Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues

                              Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.

                                DVA vs. CHE: Which Stock Should Value Investors Buy Now?

                                DVA vs. CHE: Which Stock Is the Better Value Option?

                                  Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised

                                  Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.

                                    Outpatient & Home Healthcare Stock Outlook: Prospects Bright

                                    The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.

                                      Nabaparna Bhattacharya headshot

                                      Outpatient Market Gains on Social Awareness: 3 Stocks in Focus

                                      Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.

                                        LHCG or CHE: Which Is the Better Value Stock Right Now?

                                        LHCG vs. CHE: Which Stock Is the Better Value Option?

                                          Walgreens Boots' Retail Pharmacy Strong Despite Several Woes

                                          Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.

                                            Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                                            Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.

                                              Tirthankar Chakraborty headshot

                                              New Strong Buy Stocks for June 18th

                                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                                LHCG or CHE: Which Is the Better Value Stock Right Now?

                                                LHCG vs. CHE: Which Stock Is the Better Value Option?

                                                  Envision Healthcare's (EVHC) Ratings on Review for Downgrade

                                                  Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.